strongly

Scancell reports Phase 2 data showing strongly improved outcomes in Late-Stage Melanoma with its Immunobody iSCIB1+

July 22, 2025 02:00 ET  | Source: Scancell Holdings Plc SCOPE trial of SCIB1/iSCIB1+ plus standard of care shows excellent…

2 days ago

Hydreight Reports 34% Year-Over-Year Q1 Revenue Growth, Improvement in Bottom Line Results, and Delivers Strong Performance Across Verticals

“It was an outstanding quarter. We exceeded our Q1 projections with approximately 34% YOY growth from our first two verticals,…

2 months ago